Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination

Authors: CDC

Summary of recent changes (last updated March 3, 2021)

  • Considerations broadened to include use of Janssen (Johnson & Johnson) COVID-19 vaccine.

Key Points

Under the Emergency Use Authorizationsexternal icon for COVID-19 vaccines, appropriate medical treatment for severe allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine. These interim considerations provide information on preparing for the initial assessment and management of anaphylaxis following COVID-19 vaccination.

Overview

Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination. These interim considerations provide recommendations on assessment and management of anaphylaxis following COVID-19 vaccination. Detailed information on CDC recommendations for vaccination, including contraindications and precautions to vaccination, can be found in the Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Patients should be screened prior to receipt of each vaccine dose, and those with a contraindication should not be vaccinated. A COVID-19 prevaccination questionnaire pdf icon[6 pages] is available to assist with screening.

For More Information: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html

Leave a Reply

Your email address will not be published.